Main Pipeline

For Your Healthy Life, NovMetaPharma

Fibrosis Medication (NovFS)

Pipeline
NovFS
Program Target
Fibrosis
Patient Numbers
5 Million
Development Stage
Research
NovMetaPharma develops NovFS, a (pulmonary, hepatic, etc.) fibrosis medication of first-in-class new substance.

NovMetaPharma has identified excellent anti-inflammatory and anti-fibrotic efficacies in NovFS (fibrosis medication) cell and animal testing. This confirmed the possibility of developing NovFS as fibrosis medication, and based on this, NovMetaPharma is conducting joint R&D of NovFS.

Treatment effects of idiopathic pulmonary fibrosis

Decrease of major mechanism gene expression causing idiopathic pulmonary fibrosis

Decrease of mediator genes (ECM) causing idiopathic pulmonary fibrosis

NovFS Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
Substance: cGMP level

Preclinical

License Out (E)

Clinical phase 1/2a

02

Patent Application and Registration Status
특허구분 IP Protection
Substance patent (US)
Application
2019
Registration
2020
Patent expiration (expected) year
2039
Fibrosis prevention and improvement patent (KR)
Application·Registration
2020
Patent expiration (expected) year
2040